The Time Has Come: Surgical Administration of Durable Medical Therapy in Vascular Retinal Diseases
This activity is supported by an educational grant from Genentech, a member of the Roche Group.
Overview
Provider Statement
This continuing medical education activity is provided by 
Support Statement
This activity is supported by an educational grant from Genentech, a member of the Roche Group.
Activity Description
Suboptimal outcomes in patients with retinal vascular diseases receiving intravitreal anti-vascular endothelial growth factor (VEGF) therapy have been associated with loss of adherence due to treatment burden. However, novel delivery devices and gene therapies that reduce the need for frequent dosing have now been developed. The Port Delivery System (PDS) with ranibizumab was recently FDA-approved for the management of patients with neovascular age-related macular degeneration (nAMD), while gene therapies are currently being evaluated in ongoing clinical studies. To achieve optimal efficacy and safety outcomes, these novel delivery modalities require unique surgical approaches for their implication into clinical practice. In this CME activity, experts in the field will discuss the risks and benefits of intravitreal versus surgical administration of agents used in the management of patients with retinal vascular diseases, evaluate new and emerging surgically delivered therapies that can enhance outcomes by reducing treatment burden, and provide best practices that can reduce the potential for complications when utilizing the PDS with ranibizumab or subretinal gene therapy in the management of patients with nAMD.
Target Audience
The intended audience for this activity is retina specialists and other health care professionals involved in the management of patients with retinal vascular diseases.
Learning Objectives
Upon successful completion of this activity, participants should be better able to:
- Compare the risks and benefits of intravitreal versus surgical administration of agents used in the management of retinal vascular diseases.
- Apply current evidence to practice regarding new and emerging surgically delivered therapies that can enhance outcomes in patients with retinal vascular diseases by reducing treatment burden.
- Incorporate best practices that can reduce the potential for complications when using the port delivery system or subretinal gene therapy for neovascular age-related macular degeneration.
Activity Chair
Arshad M. Khanani, MD, MA, FASRS
Managing Partner
Director of Clinical Research
Director of Fellowship
Sierra Eye Associates
Clinical Associate Professor
University of Nevada
Reno, NV
Faculty
Sara J. Haug, MD, PhD
Partner, Southwest Eye Consultants, Durango, CO
Director of Clinical Research, Southwest Retina Research Center
Durango, CO
Dante J. Pieramici, MD
Director, California Retina Research Foundation
Partner, California Retina Consultants
Santa Barbara, CA
Lejla Vajzovic, MD, FASRS
Director, Duke Surgical Vitreoretinal Fellowship Program
Director, Duke Center for Artificial and Regenerative Vision
Co-Director, Duke Pediatric Retina and Optic Nerve Center
Director, Duke Eye Center Continuing Medical Education
Director, Duke fAVS and AVS Courses
Associate Professor of Ophthalmology
Adult and Pediatric Vitreoretinal Surgery and Diseases
Duke University Eye Center
Durham, NC
Reviewer
Ronald A. Codario, MD, EMBA, FACP, FNLA, RPVI, CHCP
Accreditation
Vindico Medical Education is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
Credit Designation
Vindico Medical Education designates this enduring material for a maximum of 1.25 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
This enduring material is approved for 1 year from the date of original release, November 30, 2022, to November 29, 2023.
How to Participate in This Activity and Obtain CME Credit
To participate in this CME activity, you must read the objectives, answer the polling and pretest questions, view the content, and complete the posttest and evaluation. Provide only one (1) correct answer for each question. A satisfactory score is defined as answering 4 of the 5 posttest questions correctly. Upon receipt of the completed materials, if a satisfactory score on the posttest is achieved, Vindico Medical Education will issue an AMA PRA Category 1 Credit(s)™ certificate.
Disclosures
Vindico Medical Education adheres to the ACCME’s Standards for Integrity and Independence in Accredited Continuing Education. Any individuals in a position to control the content of a continuing education activity, including faculty, planners, reviewers, or others, are required to disclose all relevant financial relationships with ineligible entities (commercial interests). All relevant conflicts of interest have been mitigated prior to the commencement of the activity.
Activity Chair and Faculty report the following relevant financial relationship(s)
Sara J. Haug, MD, PhD
Consultant: Genentech
Arshad M. Khanani, MD, MA, FASRS
Consultant: 4DMT, Adverum, Alimera, Allergan, Apellis, AsclepiX, Aviceda, Bausch + Lomb, Broadwing Bio, Chengdu Kanghong, Cholgene, DORC, Gemini, Genentech, Glaukos, Graybug, Gyroscope, Iveric Bio, Janssen, Kato, Kodiak, Novartis, Oculis, Opthea, Oxurion, PolyPhotonix, RecensMedical, Regeneron, Retrotope, Regenxbio, RevOpsis, Roche, Thea, Unity Bio
Speaker Contracted by Ineligible Company: Allergan, Genentech, Novartis
Independent Research Contractor: 4DMT, Adverum, Apellis, AsclepiX, Chengdu Kanghong, Gemini, Genentech, Graybug, Gyroscope, Iveric Bio, Kodiak, Neurotech, NGM Bio, Novartis, Ocular Therapeutix, Oculis, Opthea, Oxurion, RecensMedical, Regenxbio, Roche, Unity Bio
Individual Stocks and Stock Options: Aviceda, PolyPhotonix, Recens Medical, Retrotope
Dante J. Pieramici, MD
Advisor: Adverum, Genentech, Iveric Bio, Regeneron, Regenxbio, Unity
Independent Research Contractor: 4DMT, Annexon, Apellis, Genentech, Gyroscope, Iveric Bio, Kodiak, Ocular Therapeutix, Ophthe, Regeneron, Regenxbio, Unity
Lejla Vajzovic, MD, FASRS
Consultant: Aerie, Alcon, Alimera, Allergan/AbbVie, Bausch + Lomb, BVI, DORC, Guidepoint, Gyroscope/Orbit Biomedical, Heidelberg Engineering, Janssen, Novartis, Oculus Surgical, Regenxbio, Roche/Genentech, Second Sight
Independent Research Contractor: AGTC, Aldeyra
Reviewer reports the following relevant financial relationship(s)
Ronald A. Codario, MD, EMBA, FACP, FNLA,
RPVI, CHCP
No relevant financial relationships to disclose.
Vindico Medical Education staff report the following relevant financial relationship(s)
No relevant financial relationships to disclose.
Signed disclosures are on file at Vindico Medical Education, Office of Medical Affairs and Compliance.
Unlabeled and Investigational Usage
The audience is advised that this continuing medical education activity may contain references to unlabeled uses of US Food and Drug Administration (FDA)–approved products or to products not approved by the FDA for use in the United States. The faculty members have been made aware of their obligation to disclose such usage. All activity participants will be informed if any speakers/authors intend to discuss either non–FDA-approved or investigational use of products/devices.
Copyright Statement
Created and published by Vindico Medical Education, 6900 Grove Road, Building 100, Thorofare, NJ 08086-9447. Telephone: 856-994-9400; Fax: 856-384-6680. Printed in the USA. © 2022 Vindico Medical Education. All rights reserved. No part of this publication may be reproduced without written permission from the publisher. The material presented at or in any of Vindico Medical Education continuing medical education activities does not necessarily reflect the views and opinions of Vindico Medical Education. Neither Vindico Medical Education nor the faculty endorse or recommend any techniques, commercial products, or manufacturers. The faculty/authors may discuss the use of materials and/or products that have not yet been approved by the US Food and Drug Administration. All readers and continuing education participants should verify all information before treating patients or utilizing any product.
CME Questions?
Contact us at cme@vindicoCME.com